Biotechnology · Healthcare
Board Member
2025-03-11–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Nurix Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NRIX alertsRoy D. Baynes, MB.Bch., M.Med., Ph.D. is recorded as Board Member at Nurix Therapeutics, Inc. (NRIX) since March 11, 2025. Nurix Therapeutics, Inc. reported in an 8-K filed August 22, 2025 that Roy D. Baynes, MB.Bch., M.Med., Ph.D. was appointed chair of the Clinical and Commercialization Committee, effective September 1, 2025. Nurix Therapeutics, Inc. reported in an 8-K filed March 13, 2025 that Roy D. Baynes, MB.Bch., M.Med., Ph.D. was appointed director, effective March 11, 2025. Nurix Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nurix Therapeutics, Inc. includes Arthur T. Sands (CEO and Board Member), Hans van Houte (CFO), Stefani Wolff (COO) and 7 others.
“In connection with Dr. Kunkel's resignation, the Board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., a member of the Board and the Clinical and Commercialization Committee, to serve as chair of the Clinical and Commercialization Committee, effective as of September 1, 2025.”
“On March 11, 2025, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., to serve as a director of the Company and as a member of the Clinical and Commercialization Committee of the Board (the “Clinical and Commercialization Committee”), effective immediately.”
SEC 8-K
2025-09-01–present
2025-03-11–present
Biotechnology · Healthcare
Board Member
2025-03-11–present